103 related articles for article (PubMed ID: 31438169)
21. Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen.
Huang CC; Kong MX; Zhou M; Rosenkrantz AB; Taneja SS; Melamed J; Deng FM
Am J Surg Pathol; 2014 Aug; 38(8):1096-101. PubMed ID: 24832163
[TBL] [Abstract][Full Text] [Related]
22. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
23. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
24. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
25. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
26. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
27. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M; Berg KD; Brasso K; Iversen P; Røder MA
Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
[TBL] [Abstract][Full Text] [Related]
28. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
[TBL] [Abstract][Full Text] [Related]
29. Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial.
Milonas D; Auskalnis S; Skulcius G; Gudinaviciene I; Jievaltas M; Joniau S
World J Urol; 2017 May; 35(5):721-728. PubMed ID: 27644229
[TBL] [Abstract][Full Text] [Related]
30. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer.
Kang J; Chen MH; Zhang Y; Moran BJ; Dosoretz DE; Katin MJ; Braccioforte MH; Salenius SA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e463-7. PubMed ID: 21944463
[TBL] [Abstract][Full Text] [Related]
31. The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer.
Nowak J; Malzahn U; Baur AD; Reichelt U; Franiel T; Hamm B; Durmus T
Acta Radiol; 2016 Jan; 57(1):107-14. PubMed ID: 25505225
[TBL] [Abstract][Full Text] [Related]
32. Favorable Gleason 3 + 4 Prostate Cancer Shows Comparable Outcomes With Gleason 3 + 3 Prostate Cancer: Implications for the Expansion of Selection Criteria for Active Surveillance.
Lee H; Lee IJ; Byun SS; Lee SE; Hong SK
Clin Genitourin Cancer; 2017 Dec; 15(6):e1117-e1122. PubMed ID: 28843377
[TBL] [Abstract][Full Text] [Related]
33. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
34. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.
Wang H; Gu L; Wu Y; Feng D; Duan J; Wang X; Huang Y; Wu S; Chen J; Luo G; Zhang X
BMC Cancer; 2017 Sep; 17(1):629. PubMed ID: 28874127
[TBL] [Abstract][Full Text] [Related]
35. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer.
Rusthoven CG; Waxweiler TV; DeWitt PE; Flaig TW; Raben D; Kavanagh BD
Urol Oncol; 2015 Feb; 33(2):71.e11-9. PubMed ID: 25151595
[TBL] [Abstract][Full Text] [Related]
36. Combining prostrate-specific antigen and Gleason score increases the diagnostic power of endorectal coil magnetic resonance imaging in prostate cancer pathological stage.
Tsao CW; Lin MH; Wu ST; Meng E; Tang SH; Chen HI; Sun GH; Yu DS; Chang SY; Cha TL
J Chin Med Assoc; 2013 Jan; 76(1):20-4. PubMed ID: 23331777
[TBL] [Abstract][Full Text] [Related]
37. Developing a model for forecasting Gleason score ≥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies.
Li X; Pan Y; Huang Y; Wang J; Zhang C; Wu J; Cheng G; Qin C; Hua L; Wang Z
Int Urol Nephrol; 2016 Apr; 48(4):535-40. PubMed ID: 26810323
[TBL] [Abstract][Full Text] [Related]
38. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
Epstein JI; Amin MB; Reuter VE; Humphrey PA
Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
[TBL] [Abstract][Full Text] [Related]
39. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
40. Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies.
Mendhiratta N; Meng X; Rosenkrantz AB; Wysock JS; Fenstermaker M; Huang R; Deng FM; Melamed J; Zhou M; Huang WC; Lepor H; Taneja SS
Urology; 2015 Dec; 86(6):1192-8. PubMed ID: 26335497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
